Enumeral Biomedical Secures $635,000 New Funding Round

  • Feed Type
  • Date
    2/11/2014
  • Company Name
    Enumeral Biomedical
  • Mailing Address
    1450 Broadway 24th Floor New York, NY 10018
  • Company Description
    Enumeral Biomedical Corp. engages in the discovery and development of native human monoclonal antibodies for use in the diagnosis and treatment of infectious, autoimmune, and inflammatory diseases, and cancers.
  • Website
    http://www.enumeral.com
  • Transaction Type
    Debt
  • Transaction Amount
    $635,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    Proceeds purposes were not disclosed. SEC regulatory filing. Contact technology company for investment details, if applicable. Not an offer or solicitation for sale of securities.
  • M&A Terms
  • Venture Investor
    Undisclosed

By posting a comment, you agree to our terms and conditions.